毛发红糠疹的治疗进展  

Update of the treatment of pityriasis rubra pilaris

作　　者：朱慧英 杨宝琦[1] ZHU Huiying;YANG Baoqi(Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and Venereology,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250022,China)

机构地区：[1]山东第一医科大学附属皮肤病医院(山东省皮肤病医院),山东省皮肤病性病防治研究所,济南250022

出　　处：《中国麻风皮肤病杂志》2022年第12期918-923,共6页China Journal of Leprosy and Skin Diseases

摘　　要：毛发红糠疹病因及发病机制不明,通常对传统治疗抵抗。由于缺乏高质量的证据,目前尚无治疗指南,维A酸类药物被普遍作为一线治疗,近年来生物制剂被证明在严重难治性病例中有快速、显著的疗效。本文就PRP治疗方法进行综述。The etiology and pathogenesis of pityriasis rubra pilaris remains unclear,and it is often resistant to conventional treatment.Due to the lack of high-quality evidence,there are currently no treatment guidelines.Retinoids are considered as first-line therapy,and in recent years biologics have been shown to have rapid and significant responses in severe refractory cases.The treatments of pityriasis rubra pilaris are reviewed.

关 键 词：毛发红糠疹 维A酸类药物 生物制剂 

分 类 号：R758.69[医药卫生—皮肤病学与性病学]